{"id":"NCT00788697","sponsor":"Bracco Diagnostics, Inc","briefTitle":"SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization","officialTitle":"Characterization of Focal Liver Lesions With SONOVUE®-Enhanced Ultrasound Imaging: A Phase III, Intrapatient Comparative Study Versus Un-enhanced Ultrasound Imaging Using Histology or Combined Imaging/Clinical Data as Truth Standard","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2013-07","completion":"2013-07","firstPosted":"2008-11-11","resultsPosted":"2017-06-14","lastUpdate":"2017-12-12"},"enrollment":349,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Liver Neoplasms"],"interventions":[{"type":"DRUG","name":"SonoVue-enhanced ultrasound","otherNames":["sulfur hexafluoride microbubbles"]},{"type":"OTHER","name":"Unenhanced ultrasound","otherNames":[]}],"arms":[{"label":"Patients who received SonoVue","type":"OTHER"}],"summary":"The purpose of this study is to demonstrate the superiority of SonoVue®-enhanced ultrasound versus unenhanced ultrasound for characterization of Focal Liver Lesions using final diagnosis based on histology or combined imaging/clinical data as truth standard.","primaryOutcome":{"measure":"Sensitivity: Percentage of True Positive Lesions Among All Malignant Lesions Per Truth Standard","timeFrame":"24 hours to 6 months","effectByArm":[{"arm":"Offsite Reader 1 - UE-US","deltaMin":53.2,"sd":null},{"arm":"Offsite Reader 1 SonoVue CE-US","deltaMin":64.5,"sd":null},{"arm":"Offsite Reader 2 - UE-US","deltaMin":41.1,"sd":null},{"arm":"Offsite Reader 2 SonoVue CE-US","deltaMin":60.5,"sd":null},{"arm":"Offsite Reader 3 UE-US","deltaMin":66.1,"sd":null},{"arm":"Offsite Reader 3 SonoVue CE-US","deltaMin":46.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0754"},{"comp":"OG002 vs OG003","p":"0.0011"},{"comp":"OG004 vs OG005","p":"0.0016"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":12},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":337},"commonTop":["Dysgeusia","Headache","Nausea","Abdominal pain","Injection site pain"]}}